HR 8205 119th Congress

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Latest Action

Became Public Law No: 119-138.

Congress.gov

Sponsors

Rep. Quigley, Mike [D-IL-5]

Rep. Quigley, Mike [D-IL-5]

D — IL

Summary

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The act reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Actions

2026-11-03T00:00:00

Became Public Law No: 119-138.

2026-11-03T00:00:00

Became Public Law No: 119-138.

2026-11-03T00:00:00

Signed by President.

2026-11-03T00:00:00

Signed by President.

2026-10-26T00:00:00

Presented to President.

2026-10-26T00:00:00

Presented to President.

2026-10-14T00:00:00

Message on Senate action sent to the House.

2026-09-28T00:00:00

Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

2026-09-28T00:00:00

Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

2026-07-23T00:00:00

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

2026-07-22T00:00:00

Motion to reconsider laid on the table Agreed to without objection.

2026-07-22T00:00:00

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

2026-07-22T00:00:00

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

2026-07-22T00:00:00

Considered as unfinished business. (consideration: CR H5159)

2026-07-20T00:00:00

At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

2026-07-20T00:00:00

DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

2026-07-20T00:00:00

Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)

2026-07-20T00:00:00

Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

2026-07-09T00:00:00

Placed on the Union Calendar, Calendar No. 637.

2026-07-09T00:00:00

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

2026-07-09T00:00:00

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

2026-05-21T00:00:00

Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.

2026-05-21T00:00:00

Committee Consideration and Mark-up Session Held

2026-05-13T00:00:00

Forwarded by Subcommittee to Full Committee by Voice Vote.

2026-05-13T00:00:00

Subcommittee Consideration and Mark-up Session Held

2026-04-06T00:00:00

Referred to the Subcommittee on Health.

2026-04-06T00:00:00

Referred to the House Committee on Energy and Commerce.

2026-04-06T00:00:00

Introduced in House

2026-04-06T00:00:00

Introduced in House

Policy Areas

Health

Track this bill on CivicBeacon

Get push notifications when this bill is updated, contact your reps, and take action.

Download on the App Store Get it on Google Play